Clinical trials for advancing innovative interventions for neurodegenerative diseases[E8]

From the notice

Call: Cluster 1 - Health (Two stage - 2027). Type of action: HORIZON Research and Innovation Actions. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The scientific and clinical communities make effective use of state-of-the-art knowledge, data, technologies, tools, methods, best practices, and trainings to underpin and complement the development of innovative interventions aimed at more effective treatments for neurodegenerative diseases. The scientific and clinical communities benefit from the exchange of data, knowledge and best practices, thereby strengthening their collaboration in the EU, the Associated Countries and beyond. The scientific and clinical communities make wide use of relevant databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR [1] principles, thereby encouraging further use of the data. Policymakers, funders, scientific and clinical communities, patient organisations, regulators, and other relevant bodies are informed of the research advances made and the requirements for a widespread implementation of the innovative therapeutic interventions and complementary approaches. Patients and caregivers are constructively engaged with the research, ensuring that their needs are catered for…[E3]

• ConditionEU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.[E4]
• The notice data states no restriction on who may bid. Exclusion grounds and selection criteria in the tender documents still apply.

• RiskThis is a grant, not a contract. Grants usually need a proposal against the funder's criteria, may need partners and often need co-funding.[E5]
• UnknownWe read the published notice, not the full tender documents.

1. Bidding opened · 29 Oct 2026, 07:41 UTC

   The source published a call for competition with a future deadline.

   Changed: status, notice type, published at (source document HORIZON-HLTH-2027-02-DISEASE-14-two-stage:31094502:2026-10-29T00:18:15.453+0100)

2. First seen · 28 Oct 2026, 21:22 UTC

   The source published a planning or prior information notice. Bidding has not opened.

   Source document HORIZON-HLTH-2027-02-DISEASE-14-two-stage:31094501:2026-10-07T11:53:34.807+0200

Every fact on this page comes from the published notice. Each entry shows the document and the field it was read from.

1. E1

   The buyer is European Commission.

   Document HORIZON-HLTH-2027-02-DISEASE-14-two-stage:31094502:2026-10-29T00:18:15.453+0100, field /metadata/type/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

2. E2

   Proposals must be submitted by 17 Feb 2027, 01:00 Central European time (UTC+1).

   “2027-02-17T00:00:00.000+0000”

   Document HORIZON-HLTH-2027-02-DISEASE-14-two-stage:31094502:2026-10-29T00:18:15.453+0100, field /metadata/deadlineDate/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

3. E3

   The buyer describes the requirement in the notice.

   “Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed…”

   Document HORIZON-HLTH-2027-02-DISEASE-14-two-stage:31094502:2026-10-29T00:18:15.453+0100, field /metadata/descriptionByte/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

4. E4

   EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.

   “EU call topic”

   Document HORIZON-HLTH-2027-02-DISEASE-14-two-stage:31094502:2026-10-29T00:18:15.453+0100, field /metadata/type/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

5. E5

   This call is open for proposals.

   “31094502”

   Document HORIZON-HLTH-2027-02-DISEASE-14-two-stage:31094502:2026-10-29T00:18:15.453+0100, field /metadata/status/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

6. E6

   The notice was published on 29 Oct 2026.

   “2026-10-29T00:00:00.000+0000”

   Document HORIZON-HLTH-2027-02-DISEASE-14-two-stage:31094502:2026-10-29T00:18:15.453+0100, field /metadata/startDate/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

7. E7

   The Funding & Tenders Portal gives the status as open for submission.

   Document HORIZON-HLTH-2027-02-DISEASE-14-two-stage:31094502:2026-10-29T00:18:15.453+0100, field /metadata/status/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

8. E8

   The notice is titled "Clinical trials for advancing innovative interventions for neurodegenerative diseases".

   Document HORIZON-HLTH-2027-02-DISEASE-14-two-stage:31094502:2026-10-29T00:18:15.453+0100, field /metadata/title/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

9. E9

   The EU contribution per grant is up to EUR 10,000,000 (from EUR 5,000,000).

   Document HORIZON-HLTH-2027-02-DISEASE-14-two-stage:31094502:2026-10-29T00:18:15.453+0100, field /metadata/budgetOverview/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0. SLETOR shortened and reformatted the text. Data licence: Creative Commons Attribution 4.0 (European Commission) ↗ (opens in a new tab). Personal contact details in notices are not stored or shown.